FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230651107> ?p ?o ?g. }

• W4230651107 endingPage "369" @default.
• W4230651107 startingPage "361" @default.
• W4230651107 abstract "Fifty-seven patients with refractory acute leukemia were treated with high-dose cytosine arabinoside to establish the maximum tolerated dose and duration and to determine the antileukemic activity. The maximum tolerated regimen was found to be 3 g/sq m every 12 hr for 6 days. At this dose, nonhematologic toxicity was limited to conjunctivitis in approximately half of the patients, and liver toxicity (transient elevations in transaminase, alkaline phosphatase, or bilirubin) was frequently observed, but neither was dose-limiting. Extending the duration of treatment to 8 days resulted in excessive diarrhea and skin toxicity (painful erythema with bullae), while increasing the dose to 4.5 g/sq m q. 12 hr for 6 days resulted in severe cerebellar toxicity. Myelosuppression was severe, but was not related to the intensity of treatment; granulocyte recovery occurred a median of 28 days (range 22- 40 days) after initiating therapy, and platelet recovery occurred after a median of 25 days (range 16–41 days). Antileukemic activity was evaluable in the 46 patients who survived at least 3 wk. Complete remissions were obtained in 1 of 6 patients with chronic myelogenous leukemia (CML) in accelerated phase and 1 of 3 acute lymphoblastic leukemia (ALL) patients. A more detailed analysis of response was possible for the 37 evaluable patients with acute nonlymphoblastic leukemia: 70% of these patients responded, with 51% complete remissions. The median unmaintained response was 4 mo (range 2–26+ mo). The complete response rate was higher in patients who received at least 12 doses of high-dose cytosine arabinoside compared to shorter regimens [17/28 (61%) versus 2/9 (22%), p less than 0.05]. Resistance to cytosine arabinoside in conventional doses was documented in 11 patients, 5 of whom responded (2 complete remissions) to high-dose regimens. We conclude that high-dose cytosine arabinoside in the maximally tolerated regimen of 3 g/sq m every 12 hr for 6 days has substantial antileukemic activity in patients refractory to standard therapy. Durable unmaintained remissions can be achieved, even in patients who fail to respond to cytosine arabinoside in conventional doses." @default.
• W4230651107 created "2022-05-11" @default.
• W4230651107 creator A5002827227 @default.
• W4230651107 creator A5011201747 @default.
• W4230651107 creator A5011576328 @default.
• W4230651107 creator A5022602598 @default.
• W4230651107 creator A5029414379 @default.
• W4230651107 creator A5060069903 @default.
• W4230651107 date "1983-08-01" @default.
• W4230651107 modified "2023-09-27" @default.
• W4230651107 title "High-dose cytosine arabinoside therapy for refractory leukemia" @default.
• W4230651107 doi "https://doi.org/10.1182/blood.v62.2.361.bloodjournal622361" @default.
• W4230651107 hasPublicationYear "1983" @default.
• W4230651107 type Work @default.
• W4230651107 citedByCount "6" @default.
• W4230651107 countsByYear W42306511072012 @default.
• W4230651107 countsByYear W42306511072016 @default.
• W4230651107 countsByYear W42306511072017 @default.
• W4230651107 countsByYear W42306511072022 @default.
• W4230651107 crossrefType "journal-article" @default.
• W4230651107 hasAuthorship W4230651107A5002827227 @default.
• W4230651107 hasAuthorship W4230651107A5011201747 @default.
• W4230651107 hasAuthorship W4230651107A5011576328 @default.
• W4230651107 hasAuthorship W4230651107A5022602598 @default.
• W4230651107 hasAuthorship W4230651107A5029414379 @default.
• W4230651107 hasAuthorship W4230651107A5060069903 @default.
• W4230651107 hasBestOaLocation W42306511071 @default.
• W4230651107 hasConcept C121332964 @default.
• W4230651107 hasConcept C126322002 @default.
• W4230651107 hasConcept C141071460 @default.
• W4230651107 hasConcept C142424586 @default.
• W4230651107 hasConcept C2778041864 @default.
• W4230651107 hasConcept C2778461978 @default.
• W4230651107 hasConcept C2781413609 @default.
• W4230651107 hasConcept C29730261 @default.
• W4230651107 hasConcept C71924100 @default.
• W4230651107 hasConcept C87355193 @default.
• W4230651107 hasConcept C90924648 @default.
• W4230651107 hasConceptScore W4230651107C121332964 @default.
• W4230651107 hasConceptScore W4230651107C126322002 @default.
• W4230651107 hasConceptScore W4230651107C141071460 @default.
• W4230651107 hasConceptScore W4230651107C142424586 @default.
• W4230651107 hasConceptScore W4230651107C2778041864 @default.
• W4230651107 hasConceptScore W4230651107C2778461978 @default.
• W4230651107 hasConceptScore W4230651107C2781413609 @default.
• W4230651107 hasConceptScore W4230651107C29730261 @default.
• W4230651107 hasConceptScore W4230651107C71924100 @default.
• W4230651107 hasConceptScore W4230651107C87355193 @default.
• W4230651107 hasConceptScore W4230651107C90924648 @default.
• W4230651107 hasIssue "2" @default.
• W4230651107 hasLocation W42306511071 @default.
• W4230651107 hasOpenAccess W4230651107 @default.
• W4230651107 hasPrimaryLocation W42306511071 @default.
• W4230651107 hasRelatedWork W2349679547 @default.
• W4230651107 hasRelatedWork W2358739720 @default.
• W4230651107 hasRelatedWork W2368167615 @default.
• W4230651107 hasRelatedWork W2375395741 @default.
• W4230651107 hasRelatedWork W2379577735 @default.
• W4230651107 hasRelatedWork W2402857688 @default.
• W4230651107 hasRelatedWork W3031323949 @default.
• W4230651107 hasRelatedWork W3032369142 @default.
• W4230651107 hasRelatedWork W765180805 @default.
• W4230651107 hasRelatedWork W87500766 @default.
• W4230651107 hasVolume "62" @default.
• W4230651107 isParatext "false" @default.
• W4230651107 isRetracted "false" @default.
• W4230651107 workType "article" @default.